Organ rejection types

Two different RO membrane types were evaluated in this study. The first was a standard cellulose acetate based asymmetric membrane. The second type, a proprietary cross-linked polyamine thin-film composite membrane supported on polysulfone backing, was selected to represent potentially improved (especially for organic rejection) membranes. Manufacturer specifications for these membranes are provided in Table III. Important considerations in the selection of both membranes were commercial availability, high rejection (sodium chloride), and purported tolerance for levels of chlorine typically found in drinking water supplies. Other membrane types having excellent potential for organic recovery were not evaluated either because they were not commercially... 

Clinical Use. Mycophenolate mofetil (CellCept) is primarily used to prevent or treat organ rejection following cardiac and renal transplantation. This drug is typically combined with other immunosuppressants (cyclosporine, glucocorticoids) to provide optimal immunosuppression in patients receiving these transplant types.39,40,70 Mycophenolate mofetil may also be useful in suppressing the immune response associated with autoimmune conditions such as systemic lupus erythematosus.2... 

The PEC-1000 membrane of Toray Industries, Inc., has been described by Kurihara et al (21). This membrane was characterized as a thin-film composite type made by an acid catalyzed polymerization on the surface. Membrane performance reported for seawater tests was 99.9 percent TDS rejection at fluxes of 5.0 to 7.4 gfd (8.3 to 12.3 L/sq m/hr) when tested with 3.5 percent synthetic seawater at 800 psi (5516 kPascals). The membrane was stable in 1500-hour tests in spiral-wrap elements and exhibited stability in a temperature range of 25 to 55°C and in a pH range from 1 to 13. High organic rejections were reported for the PEC-1000 membrane rejection of dimethylformamide from a 10 percent solution was 95 percent and similar tests with dimethylsulfoxide showed 96 percent rejection. The composition and conditions for preparation of PEC-1000 membrane is not disclosed in Reference 21. Apparently it is a dip-cast membrane related to compositions described by Kurihara, Watanaba and Inoue in Reference 18. 

Data are also available for MS patients, where supplementation with 25(OH)2D3 increased serum levels of antiinflammatory cytokine TGF-J3 after 6 months of treatment, whereas no or little effect was observed on TNF-a, IL-13, IFN-y and IL-2 [187]. No information was given on the clinical presentation of these patients after treatment. In type I diabetes, a long-term study proved dietary vitamin D supplementation was clinically beneficial in terms of reduced risk of the disease [165]. Heart transplant recipients that were treated with low-dose l,25(OH)2D3 aiming at reduction of bone loss required significantly less cyclosporin for prevention of organ rejection suggesting a potentially beneficial immunosuppressive role of l,25(OH)2D3 in transplantational medicine [188]. 

Mycophenolate mofetil (Cellcept) is an immunosuppressant approved for prophylaxis of organ rejection in patients with renal, cardiac, and hepatic transplants. Myco-phenolic acid, the active derivative of mycophenolate mofetil, inhibits the enzyme inosine monophosphatase dehydrogenase (IMPDH), thereby depleting guanosine nucleotides essential for DNA and RNA synthesis. Moreover, mycophenolic acid is a fivefold more potent inhibitor of the type 11 isoform of IMPDH found in activated B- and T-lymphocytes and thus functions as a specific inhibitor of T- and B-lymphocyte activation and proliferation. The drug also may enhance apoptosis. 

Yaginuma patented interfacial membranes made by condensation of poly-alicyclic diisocyanates and diacyl halides with polyethylenimine or polyepia-mine.44 This approach was claimed to provide high organic rejections simultaneously with low salt rejections, whereas comparative data for typical aromatic diisocyanates or diacyl halides showed high rejections for both types of solutes. However, only a wastewater product, naphthalenesulfonic acid/formaldehyde condensate, was used in the testing of such membranes. 

Table 5.7 Deposition and rejection of hematite colloids, organic rejection, and flux decline as a fraction of organic type and concentration, calcium concentration and pH (GVWP membrane, OPS).

Ferric chloride addition could improve organic rejection to values comparable with UF and NF. However, the process is potentially unreliable due to the dependence of rejection and flux on organic type and concentration, solution chemistry, and floe characteristics. 

Nanojiltration ryection depends on solute charge, concentration and si e, as mil as membrane characteristics. Consequent, the membranes used were thoroughly characterised and then tested with salt solutions and a model organic compound. Then organics rejection as a function ofpH, organic type, salt concentration and Itydrodynamic conditions was determined. 

Rejection of four membranes was studied for salt solutions and three organic types. The TFC membranes showed a high rejection of organics, which was determined by siqe exclusion. Salt rejection varied with membrane type. The TFC-SR membrane showed a high selectivity between sodium and calcium, whereas the TFC-S and TFC-UW membranes rejected large amounts organics rejection varied with solution chemistry. 

In UF, rejection and fractionation experiments showed that a molecular weight cut-off (MWCO) of smaller than 10 kDa is required to remove a substantial amount of natural organics. Rejection depends on organic type and solution chemistr). The importance of charge effects between organics and membranes was demonstrated. 

Another biomedical appHcation of mictocapsules is the encapsulation of Hve mammalian ceUs for transplantation into humans. The purpose of encapsulation is to protect the transplanted ceUs or organisms from rejection by the host. The capsule sheU must prevent entrance of harmful agents into the capsule, aUow free transport of nutrients necessary for ceU functioning into the capsule, and aUow desirable ceUular products to freely escape from the capsule. This type of encapsulation has been carried out with a number of different types of Hve ceUs, but studies with encapsulated pancreatic islets or islets of Langerhans ate most common. The alginate—poly(L-lysine) encapsulation process originally developed in 1981 (54) catalyzed much of the ceU encapsulation work carried out since. A discussion of the obstacles to the appHcation of microencapsulation in islet transplantation reviewed much of the mote recent work done in this area (55). Animal ceU encapsulation has also been researched (56). 

Antigens, however, can induce a second type of response which is known as the cell-mediated immune response. The antigenic agent stimulates the appearance of sensitized lymphocytes in the body which confer protection against organisms that have the ability to live and replicate inside the cells of the host. Certain of these lymphocytes are also involved in the rejection of tissue grafts. 

Aging (skin and other tissues), myocardial infarct or stroke, inflammation, rheumatoid arthritis, atherosclerosis, pulmonary disorders (asthma and chronic obstructive pulmonary diseases), radiation injury, organ transplant rejection, psoriasis, hypertension, AIDS, multiple types of cancer, neuro-degenerative diseases (Parkinson s), diabetes, muscular dystrophy... 

---